comparemela.com

Latest Breaking News On - Pivotal study - Page 3 : comparemela.com

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks o

First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hem

JADA Rapidly and Effectively Controlled Bleeding Due to PPH,1 Reinforcing Pivotal Study Results1PPH is a Significant Cause of Maternal Morbidities in the U.S.2,3,4,5New Exploratory Post-Hoc Analysis Examined the Relationship Between Reported Severe Maternal Morbidity (SMM) Outcomes and Cumulative Blood Loss Prior to.

Jersey-city
New-jersey
United-states
Jersey
New-york
Maryland
Patricia-carney
Dena-goffman
Alex-arzeno
Jennifer-halchak
Carvalho-pacagnella
Thromb-haemost

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications -Today at 12:08 pm

Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks This new analysis.

United-kingdom
Minnesota
United-states
Paris
France-general
France
American
British
Frederic-bard
Renaud-morin
Jorge-jacinto
Natalya-danchenko

Enspire DBS Therapy Announces the Publication of EDEN, an Early Feasibility Trial of Deep Brain Stimulation (DBS) plus Rehab for Stroke Patients, in Nature Medicine

/PRNewswire/ Enspire DBS Therapy, Inc., (Enspire) a clinical stage company developing an implantable neuromodulation therapy for post-stroke recovery,.

United-states
Prnewswire-enspire
Andre-machado
Kenneth-baker
Therapy-inc
Electrical-stimulation
Dentate-nucleus
Upper-extremity-hemiparesis-due
Ischemic-stroke
Cleveland-clinic
Chief-scientific
Pivotal-study

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones.

Switzerland
Houston
Texas
United-states
Spain
France
Italy
Jenene-thomas
John-climaco
Nasdaq
Linkedin
Company-on-twitter

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.